AfricaBusiness.com

January 24, 2013

Le Congo doit diversifier son économie et penser à l’après-pétrole

Eustache Ouayoro : « Le Congo est donc l’un des pays qui doit faire la différence en Afrique » read more

December 20, 2012

IMF and World Bank Announce US$176 million Debt Relief for the Union of the Comoros

The International Monetary Fund (IMF) and the World Bank’s International Development Association (IDA*) have decided to support US$176 million in debt relief for the Comoros, representing a 59 percent reduction of its future external debt service over a period of 40 years.[1] read more

September 24, 2012

Burundi: Country Results Profile

March 7, 2012

Medicago Inc. and Mitsubishi Tanabe Pharma Corporation Enter into a Strategic Alliance to Develop New Vaccines

Medicago to Receive up to $33 Million in Upfront and Milestone Payments as well as Royalties under a First Agreement to Develop a Rotavirus Vaccine read more

February 14, 2012

*TOGO/santé : des organisations de la société civile des régions Maritime et Lomé Commune en consultation à Lomé*

Filed under: French,Togo News — Tags: , , , , , , , , — Louis Bararmna @ 6:46 pm

Une vingtaine de représentants d’Organisations de la Société Civile (OSC) des régions sanitaires de Maritime et Lomé Commune actives dans les domaines de la santé de la mère et de l’enfant, de la vaccination et du renforcement du système de santé étaient en consultation ce 14 février 2012 à Lomé. read more

January 24, 2012

UN refugee agency warns of potential polio cases in Ethiopian camps

With Famine Crisis Thousands of Somalis Flee to Ethiopia Refugee Camps read more

January 20, 2012

Medicago Announces Expansion of Pipeline with the Development of a Vaccine for Rabies

Filed under: Science — Tags: , , , , , , , , , , , , , , , , , — AfricaBusiness.com @ 10:34 am

QUEBEC CITY, Jan. 19, 2012 /PRNewswire/ – Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has successfully completed initial studies towards the development of a new VLP vaccine candidate for rabies. Over the past 12 months, as part of the Company’s strategy to further develop a pipeline of products, Medicago has been working diligently to expand the application of its VLP technology to new vaccine targets. Several research-stage products have demonstrated positive results, and the Company is working to advance selected targets into preclinical development, including its rabies vaccine. read more

Powered by WordPress